Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.64 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | DDX3X | O00571 | 1/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13433869 | 0.89 | KMT2A (0.69) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL23011774 | 0.83 | ALDH1A1 (0.84) | KMT2AMEN1MAPTPOLBLMNA | |
| SCHEMBL13219583 | 0.81 | PTPN1 (0.75) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL7718019 | 0.80 | KMT2A (0.69) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL22362613 | 0.80 | MAPT (0.59) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL31497191 | 0.80 | KMT2A (0.64) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL28347687 | 0.80 | KMT2A (0.64) | KMT2AMEN1MAPTPOLBTHRB | |
| SCHEMBL13698359 | 0.79 | MEN1 (0.91) | KMT2AMEN1MAPTPOLBLMNA | |
| SCHEMBL9329754 | 0.79 | MEN1 (0.85) | KMT2AMEN1MAPTPOLBLMNA | |
| SCHEMBL31700364 | 0.79 | HSPD1 (1.00) | KMT2AMEN1MAPTPOLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | KMT2A 3872/4885MEN1 506/4885MAPT 2862/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KMT2A 693/4885MEN1 734/4885MAPT 517/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | KMT2A 3872/4885MEN1 506/4885MAPT 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.